Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OGT goes FISHing with Cytocell buy

This article was originally published in Clinica

Executive Summary

Genetic research specialist Oxford Gene Technology (OGT) has acquired fellow UK firm Cytocell for an undisclosed fee. In doing so, it gains a portfolio of fluorescence in situ hybridization (FISH) probes that complement its existing offering of cytogenics array and next-generation sequencing products. FISH is used to map DNA sequences, for example to detect chromosomal abnormalities such as Down’s syndrome. The FISH market is currently worth $295m and is growing at 19% per year, OGT estimates. Cambridge-based Cytocell will also strengthen OGT’s distributor network (it sells to more than 60 countries through partners, except in the UK and Germany, where it has a direct presence); and has a potential source of new products in its proprietary collection of bacterial artificial chromosome (BAC) clones. Cytocell reported sales of £4.5m, up 20% year-on-year, in its most recent fiscal year, according to OGT. The deal will be immediately accretive upon completion.

You may also be interested in...

What are the hottest innovations from Israel?

Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.

EuroPCR: St Jude and Philips talk up rival intravascular imaging techs

St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.

EuroPCR: Medtronic's drug-coated balloon keeps rising

A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts